Vanda Pharmaceuticals Inc.
VNDA
$4.36
$0.051.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -502.19% | -611.38% | -104.67% | -3,986.13% | -397.24% |
| Total Depreciation and Amortization | 2.54% | -10.84% | 70.38% | 239.14% | 226.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2,391.49% | -248.11% | 107.61% | -139.46% | -93.26% |
| Change in Net Operating Assets | 432.15% | -127.43% | -74.54% | -42.22% | 75.50% |
| Cash from Operations | -120.15% | -537.93% | 51.31% | -611.27% | 47.59% |
| Capital Expenditure | 81.68% | 83.92% | 99.79% | -570.83% | -2,867.27% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.84% | 385.94% | -92.64% | -65.44% | 92.86% |
| Cash from Investing | -0.05% | 340.98% | 109.12% | -65.87% | 92.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 993.33% | 450.00% | -234.67% | 155.74% | 42.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -38.77% | 188.91% | 103.84% | -107.41% | 89.12% |